Did you get an advance copy of the CC presentation? I'm sure this is what we'll hear. Unfortunately, you didn't copy the next line. The next line will be, "To capitalize on our leadership position, we're going to need some more money."
I'm sure the CC will stress the unlimited future potential for this science. It is like being a Cubs fan: next year is going to be our year, for sure.
They better not. Stock is less than 1% of its split adjusted IPO price. Even a 100% premium wouldn't begin to make this a fair deal for shareholders.
Who was foolish enough to pay over 25 yesterday? When a stock is down like SRPT, too many longs are simply looking to get out with reduced loss.
If you would have shorted at any price after open yesterday, you'd be in the money today. Of course that means that everyone who bought yesterday and held is now in hope mode.
All those folks who bought earlier today at 25+ hope you are right. Of course hope is a terrible investment strategy.
I don't know, but it certainly didn't take them long to write it. You'd think that if they wanted to benefit from a short position, they would have let the price go up for a day or two and then post the article. Unless of course they have already reached their maximum short commitment.
Long for too long. While I have always thought the potential was there, the company has been mismanaged from an investor's point of view. When you look at other companies in the same commercial space and without any products on the market, their valuations are many times that of ROSG.
As for the 400 in the study, that would be consistent with the sales they have been reporting thus far. You are, of course, right that studies cost money and that is consistent with what we've heard consistently from ROSG. Yet another expenditure and there is no explanation of why this is being done. We, as investors, as left to guess how this might benefit the top line.
I did look up the Angelina Effect and this has to do with breast cancer, not CUP. CUP is the focus of this study. Note also that the Angelina Effect is already a year old. If it were going to have an impact on ROSG test sales, wouldn't we have seen it by now?
Did you read the article about the follow-up on the CUP test? They are going to review 400 cases. Does that mean that they have only administered the test to 400 patients? At $4K per test, as I recall, that is only $1.6 million. Makes sense that they would conduct this follow-up; apparently physicians are not seeing the value based on the documentation thus far available.
When news doesn't drive price higher, it is yet another signal to short CLF. You know they aren't going to have any meaningful updates in the coming days and clearly no one wants to pay more based on this news of hiring bankers to sell assets. If no one is buying, you might as well sell.
If this news came out when stock was at 18, would the price have gone down to under 15 or gone up from there? It seems that news either adds or subtracts from the current price regardless of where it is in its 52 week range.